EUVIMEDEUVIMED entdecken
Crossref

Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms

Wiebke Werner, Katharina Detjen, Alix Bruneau, Isabella Lurje, Natalie Nestel, Henning Jann, Frank Tacke iD, Bertram Wiedenmann, Christoph Roderburg, Linda Hammerich iD

Endocrine-Related Cancer · 2023

DOI: 10.1530/erc-22-0357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Wiebke Werner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Charité Universitaetsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Gastrointestinal Neoplasms, Neuroendocrine Tumors, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical management of gastroenteropancreatic neuroendocrine neoplasms remains challenging. We recently introduced the FMS-like tyrosine kinase 3 ligand (FLT3LG) as a possible biomarker for a proinflammatory tumor microenvironment. Here, we put a spotlight on the quantitative assessment of classical dendritic cells (cDC) and T cells in the context of FLT3LG mRNA levels in a retrospective study on neuroendocrine tumor (NET) G2/G3 and neuroendocrine carcinoma (NEC) of pancreatic and gastric origin. The abundance of cDC and T cells and their relevant subpopulations were determined by immunofluorescent staining and correlated with FLT3LG mRNA levels as well as clinical outcomes. Immune cell counts attested to highly variable infiltration densities. Samples with the presence of cDC or high numbers of T cells exhibited increased FLT3LG expression. Abundance of cDC, defined as HLA-DR+CD11c+ cells with CLEC9a (cDC1) or CD1c (cDC2), as well as T cells correlated with FLT3LG mRNA levels and predicted disease-specific survival. Combining FLT3LG and T cell counts further improved this prediction. Therefore, tumor-infiltrating cDC and T cells are prognostic markers in NET G2/G3 or NEC and FLT3LG mRNA may serve as a simple-to-use biomarker for a quantitative estimate of their abundance, mandating prospective evaluation in the context of immune-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsGastrointestinal NeoplasmsNeuroendocrine TumorsCarcinoma, NeuroendocrineStomach NeoplasmsIntestinal NeoplasmsHumansRetrospective StudiesT-LymphocytesBiomarkersTumor Microenvironment

Stichwörter der Autor:innen

CTLFlt3LGEP-NENT cellsbiomarkercDC1immunotherapyneuroendocrine neoplasmneuroendocrine tumortumor immune microenvironment

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Charité Universitaetsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
  • Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine, University Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Frank Tacke, Linda Hammerich

Zitieren

APA

Werner, W., Detjen, K., Bruneau, A., Lurje, I., Nestel, N., Jann, H., Tacke, F., Wiedenmann, B., Roderburg, C., & Hammerich, L. (2023). Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0357

Vancouver

Werner W, Detjen K, Bruneau A, Lurje I, Nestel N, Jann H, et al. Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0357

BibTeX
@article{Werner2023,
  author = {Werner, Wiebke and Detjen, Katharina and Bruneau, Alix and Lurje, Isabella and Nestel, Natalie and Jann, Henning and Tacke, Frank and Wiedenmann, Bertram and Roderburg, Christoph and Hammerich, Linda},
  title = {Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms},
  journal = {Endocrine-Related Cancer},
  year = {2023},
  doi = {10.1530/erc-22-0357}
}
Kostenlos starten →